CINCINNATI--(BUSINESS WIRE)--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced the commencement of a Phase I/II Clinical Trial for a Parvovirus B19 Vaccine manufactured by its wholly owned subsidiary, Meridian Life Science, located in Memphis, Tennessee. The Investigational New Drug (IND) Application for the Parvovirus B19 Vaccine was a collaborative effort between Meridian Life Science and two branches of the National Institutes of Health (NIH), the National Heart, Lung, and Blood Institute (NHLBI/NIH), and the National Institute of Allergy and Infectious Diseases (NIAID/NIH). The Phase I/II Clinical Trial will be conducted at three of NIAID/NIH’s Vaccine Testing and Evaluation Units (VTEU) on behalf of the NHLBI/NIH. The VTEUs are the Cincinnati Children’s Hospital, the Baylor College of Medicine, and the University of Maryland, Baltimore. The trial has been initiated and it will evaluate the safety and immunogenicity of the Parvovirus B19 Vaccine in healthy adult human volunteers.
